NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
Clinical Trials
61 trialsNCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05308966 2025-10-06
MESO-IMMUNE
Groupe Francais De Pneumo-Cancerologie
Completed
NCT00629343 2025-06-05
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
Phase 1 Completed
NCT05455424 2025-05-15
NERO
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT04040231 2025-05-13
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03063450 2025-04-10
CONFIRM
University of Southampton
Phase 3 Completed
NCT03560973 2025-03-13
RAMES
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT03656549 2024-12-17
IMPROVE-I
Radboud University Medical Center
Phase 4 Completed
NCT05660616 2024-08-27
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
Phase 2 Completed
NCT03867578 2024-07-31
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
University of Chicago
Phase NA Completed
NCT05041062 2024-01-03
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Phase 2 Completed
NCT01401907 2023-10-19
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Massachusetts General Hospital
Phase NA Completed
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT05404022 2023-09-13
CanBenefitII
University of Hull
Phase NA Completed
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT00651456 2023-03-13
MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3 Completed
NCT01356251 2023-02-08
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02293005 2022-10-04
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02592551 2022-09-29
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Phase 2 Completed
NCT03023319 2022-06-14
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase 1 Completed
NCT03655834 2022-05-10
IMPROVE-III
Radboud University Medical Center
Phase 4 Completed
NCT04088786 2022-05-06
Phase I Trial HIPEC With Nal-irinotecan
Stony Brook University
Phase 1 Completed
NCT04481672 2022-01-11
Intravenous Magnesium in Patients Receiving Cisplatin
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02139904 2021-10-12
VIM
Wales Cancer Trials Unit
Phase 2 Completed
NCT03213301 2021-07-14
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Swiss Cancer Institute
Phase 2 Completed
NCT02716272 2021-02-10
MAPS2
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT00295503 2020-10-20
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02519049 2020-10-01
11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
Istituto Clinico Humanitas
Completed
NCT03805971 2020-04-03
Probe Based Confocal Laser Endomicroscopy During Thoracoscopy for Pleural Malignancies Diagnosis.
University of Liege
Completed
NCT01119664 2020-03-17
Combination Gene Transfer and Chemotherapy
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02194231 2020-01-23
ATREUS
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT00859469 2019-10-30
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Columbia University
Phase 2 Completed
NCT00188890 2019-10-07
Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers
University Health Network, Toronto
Completed
NCT04056026 2019-09-23
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
ProgenaBiome
Phase EARLY_PHASE1 Completed
NCT02958683 2019-02-22
CWM
Heart of England NHS Trust
Completed
NCT02599194 2019-01-03
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University
Phase 2 Completed
NCT01776385 2018-07-23
The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma
Centre Hospitalier Universitaire de Nice
Phase NA Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01590472 2017-11-07
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Wake Forest University Health Sciences
Completed
NCT01134146 2017-07-21
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01204203 2017-05-24
UAB0901
University of Alabama at Birmingham
Phase 2 Completed
NCT01211275 2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03034850 2017-01-27
Thrombin Generation and Platelet Activation in CRS/HIPEC
Ziekenhuis Oost-Limburg
Completed
NCT00571298 2017-01-23
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02834234 2016-07-26
Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays
Hospices Civils de Lyon
Completed
NCT00469196 2016-04-06
Tomotherapy Treatment for Mesothelioma
AHS Cancer Control Alberta
Phase 2 Completed
NCT00402766 2015-11-18
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed